Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyArmando Santoro, Camillo Porta, Stefania Salvagni et al.|The Lancet Oncology|2012Cited by 550
Dynamic optimization in future cellular networksS.C. Borst, Philip Whiting, Arumugam Buvaneswari et al.|Bell Labs Technical Journal|2005Cited by 32